Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL688626 | 0.91 | FBP1 (0.48) | KMT2AMAPTMEN1GAAABCB1 | |
| SCHEMBL689175 | 0.91 | FBP1 (0.48) | KMT2AMAPTMEN1GAAABCB1 | |
| SCHEMBL13587122 | 0.88 | KMT2A (0.42) | KMT2AMAPTMEN1GAASMN1; SMN2 | |
| SCHEMBL13587120 | 0.88 | KMT2A (0.42) | KMT2AMAPTMEN1GAASMN1; SMN2 | |
| SCHEMBL12971389 | 0.87 | MEN1 (0.44) | KMT2AMAPTMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL10024674 | 0.82 | KMT2A (0.37) | KMT2AMAPTMEN1GAASMN1; SMN2 | |
| SCHEMBL14025830 | 0.82 | LMNA (0.48) | KMT2AMAPTMEN1GAASMN1; SMN2 | |
| SCHEMBL13598058 | 0.81 | CNR1 (0.41) | KMT2AMAPTMEN1GAASMN1; SMN2 | |
| SCHEMBL13587123 | 0.81 | SMN1; SMN2 (0.38) | KMT2AMAPTMEN1GAASMN1; SMN2 | |
| SCHEMBL13597945 | 0.80 | SMN1; SMN2 (0.41) | KMT2AMAPTMEN1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038545-A1 | HYDROXYPHENYL PYRROLE COMPOUNDS CONTAINING AN HYDROXAMIC ACID AS HDAC INHIBITORS AND MEDICINAL APPLICATIONS THEREOF | Universidad Del País Vasco (ES) | 2015-02-05 | — | — | US | disclosed |
| EP-2508510-A1 | Hydroxyphenyl pyrrole compounds containing an hydroxamic acid as hdac inhibitors and medicinal applications thereof | Ikerchem, S.L. (ES) | 2012-10-10 | — | — | EP | disclosed |
| EP-1975158-B9 | NOVEL PYRROLE DERIVATIVES WITH HISTONE DEACETYLASE INHIBITOR ACTIVITY | UNIV PAIS VASCO (ES) | 2012-02-29 | — | — | EP | disclosed |
| EP-1975158-B1 | NOVEL PYRROLE DERIVATIVES WITH HISTONE DEACETYLASE INHIBITOR ACTIVITY | UNIV PAIS VASCO (ES) | 2011-07-13 | — | — | EP | disclosed |
| US-7638550-B2 | new compounds derived from formula I pyrroles, methods for obtaining them and their application as drugs in pharmaceutical compositions for the treatment of cancer due to their inhibitory activity on certain histone deacetylases. | Universidad del Pais Vasco-Euskal Herriko Unibertsitatea (UPV-EHU) Fundacion Centro Nacional de Investigaciones Oncologicas Carlos III (CNIO) (ES) | 2009-12-29 | — | — | US | disclosed |
| US-20080262073-A1 | Pyrrolic Derivatives with Histone Deacetylase Inhibitory Activity | FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (CNIO) (ES) | 2008-10-23 | — | — | US | disclosed |
| EP-1975158-A1 | NOVEL PYRROLE DERIVATIVES WITH HISTONE DEACETYLASE INHIBITOR ACTIVITY | UNIVERSIDAD DEL PAIS VASCO-EUSKAL HERRIKO UNIBERSITATEA (ES) | 2008-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262073-A1 | Pyrrolic Derivatives with Histone Deacetylase Inhibitory Activity | HDAC1, HDAC11, HDAC5 | KMT2A 71/4885MAPT 3317/4885MEN1 4099/4885 |
| US-20150038545-A1 | HYDROXYPHENYL PYRROLE COMPOUNDS CONTAINING AN HYDROXAMIC ACID AS HDAC INHIBITORS AND MEDICINAL APPLICATIONS THEREOF | HDAC1, HDAC5, HDAC2 | KMT2A 37/4885MAPT 1685/4885MEN1 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.